ERBB2 and breast carcinoma: Following no reverse causation between critically ill COVID-19 and the risk of HER2-positive breast cancer (OR = 1.001, 95% CI = 0.948–1.054, P = .994), we sought to identify immune cells with the mediating effect of critically ill COVID-19 on the risk of HER2-positive breast cancer.